Ionis Has Expanded Its Existing Collaboration With AstraZeneca To Include Exclusive Rights For AstraZeneca To Commercialize Eplontersen In Latin America. Ionis Previously Granted Astrazeneca Exclusive Rights To Commercialize Eplontersen Outside US
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize Eplontersen in Latin America. The two companies will continue to jointly develop and commercialize Eplontersen in the U.S.
July 28, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ionis Pharmaceuticals has expanded its collaboration with AstraZeneca, granting the latter exclusive rights to commercialize Eplontersen in Latin America.
While the expansion of the collaboration with AstraZeneca could potentially increase Ionis' revenues, the impact on its stock price in the short term is uncertain as it depends on the financial terms of the deal, which are not disclosed in the news.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
AstraZeneca has gained exclusive rights to commercialize Eplontersen in Latin America through its expanded collaboration with Ionis.
The news of AstraZeneca gaining exclusive rights to commercialize Eplontersen in Latin America could potentially boost its revenues in the region, which may positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80